Pre-treatment with dopamine agonists influence l-dopa mediated rotations without affecting abnormal involuntary movements in the 6-OHDA lesioned rat

Behavioural Brain Research

Volumn 213, Issue 1, 2010, Pages 66-72

  Lane, Emma L ^a   Dunnett, Stephen B ^a  

^a CARDIFF UNIVERSITY   (United Kingdom)

Author keywords

6 OHDA lesioned rat; Dopamine agonist; Dyskinesia; L dopa; Parkinson's disease

Indexed keywords

BENSERAZIDE; BROMOCRIPTINE; LEVODOPA; OXIDOPAMINE; PIRIBEDIL; PRODYNORPHIN; ROPINIROLE; SODIUM CHLORIDE;

ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CHRONIC DRUG ADMINISTRATION; CIRCLING BEHAVIOR; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFICACY; DYSKINESIA; GENE EXPRESSION; INVOLUNTARY MOVEMENT; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; SENSITIZATION; TREATMENT DURATION;

ANIMALS; ANTIPARKINSON AGENTS; BROMOCRIPTINE; CORPUS STRIATUM; DOPAMINE AGONISTS; DYSKINESIA, DRUG-INDUCED; ENKEPHALINS; FEMALE; INDOLES; LEVODOPA; OXIDOPAMINE; PARKINSONIAN DISORDERS; PIRIBEDIL; PROTEIN PRECURSORS; RATS; RATS, SPRAGUE-DAWLEY; RNA, MESSENGER; ROTATION; TIME FACTORS;

EID: 77953359266     PISSN: 01664328     EISSN: 18727549     Source Type: Journal    
DOI: 10.1016/j.bbr.2010.04.034     Document Type: Article

References (31)

1. Ahlskog J.E., Muenter M.D. Frequency of levodopa-related dyskinesias and motor fluctuations as estimated from the cumulative literature. Mov Disord 2001, 16:448-458.
2. Olanow C.W., Agid Y., Mizuno Y., Albanese A., Bonuccelli U., Damier P., et al. Levodopa in the treatment of Parkinson's disease: current controversies. Mov Disord 2004, 19:997-1005.
3. Grondin R., Goulet M., Di Paolo T., Bedard P.J. Cabergoline, a long-acting dopamine D2-like receptor agonist, produces a sustained antiparkinsonian effect with transient dyskinesias in parkinsonian drug-naive primates. Brain Res 1996, 735:298-306.
4. Jackson M.J., Smith L.A., Al-Barghouthy G., Rose S., Jenner P. Decreased expression of l-dopa-induced dyskinesia by switching to ropinirole in MPTP-treated common marmosets. Exp Neurol 2007, 204:162-170.
5. Pearce R.K., Banerji T., Jenner P., Marsden C.D. De novo administration of ropinirole and bromocriptine induces less dyskinesia than l-dopa in the MPTP-treated marmoset. Mov Disord 1998, 13:234-241.
6. Rascol O., Brooks D.J., Korczyn A.D., De Deyn P.P., Clarke C.E., Lang A.E. A five-year study of the incidence of dyskinesia in patients with early Parkinson's disease who were treated with ropinirole or levodopa. 056 Study Group. N Engl J Med 2000, 342:1484-1491.
7. Smith L.A., Jackson M.J., Johnston L., Kuoppamaki M., Rose S., Al-Barghouthy G., et al. Switching from levodopa to the long-acting dopamine D2/D3 agonist piribedil reduces the expression of dyskinesia while maintaining effective motor activity in MPTP-treated primates. Clin Neuropharmacol 2006, 29:112-125.
8. Doucet J.P., Nakabeppu Y., Bedard P.J., Hope B.T., Nestler E.J., Jasmin B.J., et al. Chronic alterations in dopaminergic neurotransmission produce a persistent elevation of deltaFosB-like protein(s) in both the rodent and primate striatum. Eur J Neurosci 1996, 8:365-381.
9. Westin J.E., Andersson M., Lundblad M., Cenci M.A. Persistent changes in striatal gene expression induced by long-term l-DOPA treatment in a rat model of Parkinson's disease. Eur J Neurosci 2001, 14:1171-1176.
10. Belanger N., Gregoire L., Hadj Tahar A., Bedard P.J. Chronic treatment with small doses of cabergoline prevents dopa-induced dyskinesias in parkinsonian monkeys. Mov Disord 2003, 18:1436-1441.
11. Cristina S., Zangaglia R., Mancini F., Martignoni E., Nappi G., Pacchetti C. High-dose ropinirole in advanced Parkinson's disease with severe dyskinesias. Clin Neuropharmacol 2003, 26:146-150.
12. Hauser R.A., Rascol O., Korczyn A.D., Jon Stoessl A., Watts R.L., Poewe W., et al. Ten-year follow-up of Parkinson's disease patients randomized to initial therapy with ropinirole or levodopa. Mov Disord 2007, 22:2409-2417.
13. Inzelberg R., Schechtman E., Nisipeanu P. Cabergoline, pramipexole and ropinirole used as monotherapy in early Parkinson's disease: an evidence-based comparison. Drugs Aging 2003, 20:847-855.
14. Hadj Tahar A., Gregoire L., Bangassoro E., Bedard P.J. Sustained cabergoline treatment reverses levodopa-induced dyskinesias in parkinsonian monkeys. Clin Neuropharmacol 2000, 23:195-202.
15. Nyholm D. Pharmacokinetic optimisation in the treatment of Parkinson's disease: an update. Clin Pharmacokinet 2006, 45:109-136.
16. Olanow C.W., Watts R.L., Koller W.C. An algorithm (decision tree) for the management of Parkinson's disease (2001): treatment guidelines. Neurology 2001, 56:S1-S88.
17. Rascol O., Brooks D.J., Korczyn A.D., De Deyn P.P., Clarke C.E., Lang A.E., et al. Development of dyskinesias in a 5-year trial of ropinirole and l-dopa. Mov Disord 2006, 21:1844-1850.
18. Lindgren H.S., Rylander D., Ohlin K.E., Lundblad M., Cenci M.A. The "motor complication syndrome" in rats with 6-OHDA lesions treated chronically with l-DOPA: relation to dose and route of administration. Behav Brain Res 2007, 177:150-159.
19. Cenci M.A., Lee C.S., Bjorklund A. l-DOPA-induced dyskinesia in the rat is associated with striatal overexpression of prodynorphin- and glutamic acid decarboxylase mRNA. Eur J Neurosci 1998, 10:2694-2706.
20. Henry B., Crossman A.R., Brotchie J.M. Characterization of enhanced behavioral responses to l-DOPA following repeated administration in the 6-hydroxydopamine-lesioned rat model of Parkinson's disease. Exp Neurol 1998, 151:334-342.
21. Prikhojan A., Brannan T., Yahr M.D. Comparative effects of repeated administration of dopamine agonists on circling behavior in rats. J Neural Transm 2000, 107:1159-1164.
22. Smith L.A., Tel B.C., Jackson M.J., Hansard M.J., Braceras R., Bonhomme C., et al. Repeated administration of piribedil induces less dyskinesia than l-dopa in MPTP-treated common marmosets: a behavioural and biochemical investigation. Mov Disord 2002, 17:887-901.
23. Winkler C., Kirik D., Bjorklund A., Cenci M.A. l-DOPA-induced dyskinesia in the intrastriatal 6-hydroxydopamine model of parkinson's disease: relation to motor and cellular parameters of nigrostriatal function. Neurobiol Dis 2002, 10:165-186.
24. Paxinos G., Watson C. The rat brain in stereotaxic coordinates 1998, Academic Press, San Diego, USA. 4th ed.
25. Lundblad M., Andersson M., Winkler C., Kirik D., Wierup N., Cenci M.A. Pharmacological validation of behavioural measures of akinesia and dyskinesia in a rat model of Parkinson's disease. Eur J Neurosci 2002, 15:120-132.
26. Ravenscroft P., Chalon S., Brotchie J.M., Crossman A.R. Ropinirole versus l-DOPA effects on striatal opioid peptide precursors in a rodent model of Parkinson's disease: implications for dyskinesia. Exp Neurol 2004, 185:36-46.
27. Antonini A., Tolosa E., Mizuno Y., Yamamoto M., Poewe W.H. A reassessment of risks and benefits of dopamine agonists in Parkinson's disease. Lancet Neurol 2009, 8:929-937.
28. Dekundy A., Lundblad M., Danysz W., Cenci M.A. Modulation of l-DOPA-induced abnormal involuntary movements by clinically tested compounds: further validation of the rat dyskinesia model. Behav Brain Res 2007, 179:76-89.
29. Lundblad M., Vaudano E., Cenci M.A. Cellular and behavioural effects of the adenosine A2a receptor antagonist KW-6002 in a rat model of l-DOPA-induced dyskinesia. J Neurochem 2003, 84:1398-1410.
30. Cenci M.A., Tranberg A., Andersson M., Hilbertson A. Changes in the regional and compartmental distribution of FosB- and JunB-like immunoreactivity induced in the dopamine-denervated rat striatum by acute or chronic l-dopa treatment. Neuroscience 1999, 94:515-527.
31. Henry B., Duty S., Fox S.H., Crossman A.R., Brotchie J.M. Increased striatal pre-proenkephalin B expression is associated with dyskinesia in Parkinson's disease. Exp Neurol 2003, 183:458-468.